MELISI, Davide
MELISI, Davide
DIPARTIMENTO DI MEDICINA
A novel modified CpG agonist of TLR-9 inhibits EGF receptor signalling and synergistically enhances antitumor activity of cetuximab and irinotecan eradicating colon cancer xenografts
2005-01-01 Tortora, Giampaolo; Bianco, R.; Caputo, R.; D'Armiento, F.; Melisi, Davide; Bianco, A. R.; De Placido, S.; Agrawal, S.; Ciardiello, F.; Damiano, V.
A novel modified CpG inhibits EGF receptor signalling and synergistically enhances antitumor activity of cetuximab and irinotecan in colon cancer xenografts.
2005-01-01 Tortora, Giampaolo; Bianco, R.; Caputo, R.; D'Armiento, F.; Melisi, Davide; Bianco, A. R.; De Placido, S.; Agrawal, S.; Ciardiello, F.; Damiano, V.
A selective cyclooxygenase-2 inhibitor combined with the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa') and protein kinase A antisense causes cooperative tumor growth inhibition after oral administration
2002-01-01 Tortora, Giampaolo; Caputo, R.; Damiano, V.; Melisi, Davide; Bianco, R.; Fontanini, G.; Bianco, A. R.; Ciardiello, F.
Anti- VEGF treatment resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype
2011-01-01 Carbone, C.; Moccia, T.; Zhu, C.; Paradiso, G.; Budillon, A.; Chiao, P. J.; Abbruzzese, J. L.; Melisi, Davide
Antitumor efficacy of the novel poly(ADP-ribose) polymerase (PARP-1) inhibitor BSI-401 and synergism with oxaliplatin (OX) in an orthotopic murine model of pancreatic cancer (PC)
2009-01-01 Melisi, Davide; Ossovskaya, V.; Sherman, B. M.; Abbruzzese, J. L.; Chiao, P. J.
Cooperative antitumor and antiangiogenic activity after oral administration of a novel taxane, an antisense targeting protein kinase A and the EGF receptor inhibitor Iressa
2001-01-01 Damiano, V.; Caputo, R.; Fontanini, G.; Faviana, P.; Melisi, Davide; De Placido, S.; Zunino, F.; Bianco, A. R.; Ciardiello, F.; Tortora, Giampaolo
ESGAR 2018 Book of Abstracts
2018-01-01 Sarno, A.; Tedesco, G.; De Robertis, R.; Paiella, S.; Salvia, R.; Frigerio, I.; Girelli, R.; Melisi, D.; Bassi, C.; D‘onofrio, M.
Gefitinib ('Iressa, ZD1839') and a second generation antisense targeting murine double minute 2 (Mdm2) synergistically inhibit tumor growth and angiogenesis in hormone-refractory prostate cancer
2003-01-01 Bianco, R.; Caputo, R.; Caputo, R.; Damiano, V.; Melisi, Davide; Bianco, R.; Ciardiello, F.; Tortora, Giampaolo
Human cancer cells with acquired resistance to anti-EGFR therapy are inhibited by VEGF- and EGFR-receptors tyrosine kinase inhibitor ZD6474
2004-01-01 Bianco, R.; Caputo, R.; Caputo, R.; Damiano, V.; Troiani, T.; Melisi, Davide; Bianco, A. R.; Tortora, Giampaolo; Ciardiello, F.
Novel anticancer drugs TLR9 agonists interfere with EGFR signaling and potently synergies with EGFR inhibitors and with bevacizumab in wild type and cetuximab-resistant colon cancer xenografts
2007-01-01 Tortora, Giampaolo; Caputo, R.; Bianco, R.; Garofalo, S.; Racioppi, L.; De Placido, S.; Ciardiello, F.; Agrawal, S.; Melisi, Davide; Damiano, V.
Novel Toll-like receptor 9 (TLR9) agonist IMO inhibits tumor growth and cooperates with cetuximab in K-Ras mutant colon and pancreatic cancer
2009-01-01 Rosa, R.; Melisi, Davide; Damiano, V.; Bianco, R.; Gelardi, T.; Garofalo, S.; Formisano, L.; Nappi, ; Marciano, R.; Tortora, Giampaolo
Pro-inflammatory factors secreted by pancreatic cancers with evasive resistance to anti-VEGF treatment contribute to malignant progression by inducing EMT
2011-01-01 Carbone, C.; Moccia, T.; Zhu, C.; Paradiso, G.; Simbolo, Michele; Budillon, A.; Chiao, P. J.; Abbruzzese, J. L.; Melisi, Davide
R1507, the human monoclonal antibody targeting the Insulin-like Growth Factor Receptor (IGF-1R), in combination with cetuximab can reverse acquired resistance to cetuximab in pancreatic and colon cancer models
2010-01-01 Melisi, Davide; Rosa, R.; Bianco, R.; Carmine, C.; Tortora, Giampaolo; Budillon, A.; Abbuzzese, J. L.; Chiao, P. J.; Javle, M.
Serum CA 19-9 level as a surrogate marker for prognosis in locally advanced pancreatic cancer (LAPC).
2008-01-01 Fogelman, D. R.; Pathak, P.; Qiao, W.; Chadha, R.; Jhamb, J.; Melisi, Davide; Wolff, R. A.; Abbruzzese, J. L.; Javle, M. M.
Targeting transforming growth factor beta (TGFbeta) type I receptor kinase activity: a therapeutic approach to suppress metastatic processes in human pancreatic cancer (HPC)
2007-01-01 Melisi, Davide; Ishiyama, S.; Sclabas, G. M.; Tortora, Giampaolo; Abbruzzese, J. L.; Chaio, P. J.
TGF-beta activated kinase 1 (TAK1) is a drugable target for pancreatic cancer (PC)
2009-01-01 Melisi, Davide; Xia, Q.; Abbruzzese, J. L.; Chiao, P. J.
TGF-beta-activated Kinase 1 (TAK1) is a therapeutic target modulating pancreatic cancer chemoresistance
2010-01-01 Melisi, Davide; Xia, Q.; Moccia, T.; Paradiso, G.; Carbone, C.; Ling, J.; Abbruzzese, J. L.; Budillon, A.; Chiao, P. J.
TGF-beta-activated kinase 1 (TAK1) is an in vivo druggable target for reverting pancreatic cancer chemoresistance
2009-01-01 Melisi, Davide; Xia, Q.; Abbruzzese, J. L.; Chiao, P. J.
The novel poly(ADP-ribose) polymerase (PARP)-1 inhibitor, BSI-401, has anti tumor activity and potentiates oxaliplatin cytotoxic activity in human pancreatic cancer
2007-01-01 Melisi, Davide; Ossovskaya, V.; Sherman, B.; Abbruzzese, J. L.; Chiao, P. J.
The protein kinase C beta antagonist enzastaurin (LY317615.HCl) inhibits cancer cell growth by multiple mechanisms and is active in EGFR inhibitors-resistant cancer cells
2006-01-01 Bianco, R.; Damiano, V.; Gelardi, T.; Daniele, G.; Caputo, R.; Melisi, Davide; Bianco, A. R.; Lahn, M; Ciardiello, F; Tortora, Giampaolo